Use of insulin immunoassays in clinical studies involving rapid-acting insulin analogues: Bi-insulin IRMA preliminary assessment
-
Arnaud Agin
Abstract
Background: In clinical studies involving rapid-acting analogues (RAAs), insulin immunoreactivity is frequently measured, including endogenous, regular insulin (RI) and RAA immunoreactivities. Such a procedure implies equivalent cross-reactivities of all insulins present in serum. Commercially available human insulin immunoassays have been widely used, but their limitations (including hemolysis and anti-insulin antibodies) were not fully investigated. The aims of our study were to compare cross-reactivities of RI and RAAs in buffer and in serum and to investigate insulin immunoassay pitfalls.
Methods: Cross-reactivities were assessed using Bi-insulin IRMA (Schering Cis-Bio International) in phosphate-buffered saline (PBS)-1% bovine serum albumin (BSA) and in pools of sera spiked with RI and RAAs (lispro and aspart). To investigate the influence of hemolysis, a pool of sera spiked with RAA was mixed with a concentrated hemolysate (final hemoglobin concentration 10g/L) and incubated for 3h at room temperature. To determine interference by anti-insulin antibodies, insulin was removed using charcoal from 18 sera with anti-insulin antibodies and from 17 sera without detectable anti-insulin antibodies. These insulin-free samples were then spiked with RI and RAAs and the immunoreactivity was determined.
Results: Compared with buffer, cross-reactivity in serum for RI, lispro and aspart was lower (35%, 29% and 26% lower, respectively). Hemolysis degraded almost all RI and RAAs contained in the serum (≥95%). Anti-insulin antibody interference was significant for RI and RAAs (p≤0.004) and correlated with anti-insulin antibody level in the serum (p≤0.001).
Conclusions: In serum, RI and RAA cross-reactivities are slightly lower than in buffer. For RAA assessment, hemolysed samples should be discarded and anti-insulin antibodies should be removed from samples before immunoreactivity measurements.
Clin Chem Lab Med 2006;44:1379–82.
References
1. Chevenne D, Trivin F, Porquet D. Insulin assays and reference values. Diabetes Metab 1999; 25:459–76.Suche in Google Scholar
2. Clark PM. Assays for insulin, proinsulin(s) and C-peptide. Ann Clin Biochem 1999; 36:541–64.10.1177/000456329903600501Suche in Google Scholar
3. Crowther NJ, Gray IP. Immunometric assays of insulin and its precursors. J Clin Ligand Assay 1996; 19:112–20.Suche in Google Scholar
4. Bowsher RR, Lynch RA, Brown-Augsburger P, Santa PF, Legan WE, Woodworth JR, et al. Sensitive RIA for the specific determination of insulin lispro. Clin Chem 1999; 45:104–10.10.1093/clinchem/45.1.104Suche in Google Scholar
5. Andersen L, Jørgensen PN, Jensen LB, Walsh D. A new insulin immunoassay specific for the rapid-acting analog, insulin aspart, suitable for bioavailability, bioequivalence, and pharmacokinetic studies. Clin Biochem 2000; 33:627–33.10.1016/S0009-9120(00)00183-1Suche in Google Scholar
6. Rave KM, Nosek L, de la Peña A, Seger M, Ernest CS, Heinemann L, et al. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care 2005; 28:2400–5.10.2337/diacare.28.10.2400Suche in Google Scholar PubMed
7. Griffen SC, Oostema K, Stanhope KL, Graham J, Styne DM, Glaser N, et al. Administration of lispro insulin with meals improves glycemic control, increases circulating leptin, and suppresses ghrelin, compared with regular/NPH insulin in female patients with type 1 diabetes. J Clin Endocrinol Metab 2006; 91:485–91.10.1210/jc.2005-1338Suche in Google Scholar PubMed
8. Chevenne D, Letailleur A, Trivin F, Porquet D. Effect of hemolysis on the concentration of insulin in serum determined by RIA and IRMA. Clin Chem 1998; 44:354–6.10.1093/clinchem/44.2.354Suche in Google Scholar
9. El Kenz H, Bergmann P. Evaluation of immunochemiluminometric assays for the measurement of insulin and C-peptide using the ADVIA Centaur. Clin Lab 2004; 50:171–4.Suche in Google Scholar
10. Sapin R. The interference of insulin antibodies in insulin immunometric assays. Clin Chem Lab Med 2002; 40:705–8.10.1515/CCLM.2002.121Suche in Google Scholar PubMed
11. Owen WE, Roberts WL. Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays. Clin Chem 2004; 50:257–9.10.1373/clinchem.2003.026625Suche in Google Scholar PubMed
12. Moriyama M, Hayashi N, Ohyabu C, Mukai M, Kawano S, Kumagai S. Performance evaluation and cross-reactivity from insulin analogs with the ARCHITECT insulin assay. Clin Chem 2006; 52:1423–6.10.1373/clinchem.2005.065995Suche in Google Scholar PubMed
13. Sapin R, Le Galudec V, Gasser F, Pinget M, Grucker D. Elecsys insulin assay: free insulin determination and the absence of cross-reactivity with insulin lispro. Clin Chem 2001; 47:602–5.10.1093/clinchem/47.3.602Suche in Google Scholar
14. Lindström T, Hedman CA, Arnqvist HJ. Use of a novel double-antibody technique to describe the pharmacokinetics of rapid-acting insulin analogs. Diabetes Care 2002; 25:1049–54.10.2337/diacare.25.6.1049Suche in Google Scholar PubMed
15. Marshall MO, Heding LG, Villumsen J, Akerblom HK, Baevre H, Dahlquist G, et al. Development of insulin antibodies, metabolic control and B-cell function in newly diagnosed insulin dependent diabetic children treated with monocomponent human insulin or monocomponent porcine insulin. Diabetes Res 1988; 9:169–75.Suche in Google Scholar
16. Fineberg NS, Fineberg ES, Anderson JH, Birkett MA, Gibson RG, Hufferd S. Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes 1996; 45:1750–4.10.2337/diab.45.12.1750Suche in Google Scholar PubMed
17. Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Råstam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002; 25:876–82.10.2337/diacare.25.5.876Suche in Google Scholar PubMed
©2006 by Walter de Gruyter Berlin New York
Artikel in diesem Heft
- Renal function – estimation of glomerular filtration rate
- Research translation: a new frontier for clinical laboratories
- Association of APOA5 c.553G>T polymorphism with type 2 diabetes mellitus in a Chinese population
- MTRR 66A>G polymorphism in relation to congenital heart defects
- Increased homocysteine in heart failure: a result of renal impairment?
- Urine flow cytometry and detection of glomerular hematuria
- Chymotrypsin effects on the determination of sperm parameters and seminal biochemistry markers
- Evaluation of cardiac involvement following major orthopedic surgery
- Increased sensitivity in detecting renal impairments by quantitative measurement of marker protein excretion compared to detection of pathological particles in urine sediment analysis
- Clinical chemistry reference values for 75-year-old apparently healthy persons
- Serum pro-hepcidin concentrations and their responses to oral iron supplementation in healthy subjects manifest considerable inter-individual variation
- Comparability of five analytical systems for the determination of triiodothyronine, thyroxine and thyroid-stimulating hormone
- Automated analysis of pleural fluid total and differential leukocyte counts with the Sysmex XE-2100
- Automation and validation of a fast method for the assessment of in vivo oxidative stress levels
- Analytical validation of the new plasma calibrated Accu-Chek® Test Strips (Roche Diagnostics)
- Use of insulin immunoassays in clinical studies involving rapid-acting insulin analogues: Bi-insulin IRMA preliminary assessment
- Analytical and clinical evaluation of a new heart-type fatty acid-binding protein automated assay
- A caveat for OV-Monitor (CA 125 antigen) measurement: something is improving, something is not
- Reply to the letter written by Dorizzi et al.
Artikel in diesem Heft
- Renal function – estimation of glomerular filtration rate
- Research translation: a new frontier for clinical laboratories
- Association of APOA5 c.553G>T polymorphism with type 2 diabetes mellitus in a Chinese population
- MTRR 66A>G polymorphism in relation to congenital heart defects
- Increased homocysteine in heart failure: a result of renal impairment?
- Urine flow cytometry and detection of glomerular hematuria
- Chymotrypsin effects on the determination of sperm parameters and seminal biochemistry markers
- Evaluation of cardiac involvement following major orthopedic surgery
- Increased sensitivity in detecting renal impairments by quantitative measurement of marker protein excretion compared to detection of pathological particles in urine sediment analysis
- Clinical chemistry reference values for 75-year-old apparently healthy persons
- Serum pro-hepcidin concentrations and their responses to oral iron supplementation in healthy subjects manifest considerable inter-individual variation
- Comparability of five analytical systems for the determination of triiodothyronine, thyroxine and thyroid-stimulating hormone
- Automated analysis of pleural fluid total and differential leukocyte counts with the Sysmex XE-2100
- Automation and validation of a fast method for the assessment of in vivo oxidative stress levels
- Analytical validation of the new plasma calibrated Accu-Chek® Test Strips (Roche Diagnostics)
- Use of insulin immunoassays in clinical studies involving rapid-acting insulin analogues: Bi-insulin IRMA preliminary assessment
- Analytical and clinical evaluation of a new heart-type fatty acid-binding protein automated assay
- A caveat for OV-Monitor (CA 125 antigen) measurement: something is improving, something is not
- Reply to the letter written by Dorizzi et al.
